Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty

J Cardiovasc Med (Hagerstown). 2021 Apr 1;22(4):317-319. doi: 10.2459/JCM.0000000000001042.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenosine Monophosphate / administration & dosage
  • Adenosine Monophosphate / adverse effects
  • Adenosine Monophosphate / analogs & derivatives*
  • Aged
  • Anxiety / etiology
  • Anxiety / therapy
  • Chest Pain / diagnosis
  • Coronary Angiography / methods
  • Coronary Occlusion* / diagnostic imaging
  • Coronary Occlusion* / drug therapy
  • Coronary Occlusion* / surgery
  • Drug Substitution / methods
  • Drug-Eluting Stents
  • Drug-Related Side Effects and Adverse Reactions* / etiology
  • Drug-Related Side Effects and Adverse Reactions* / therapy
  • Dyspnea* / etiology
  • Dyspnea* / physiopathology
  • Dyspnea* / therapy
  • Electrocardiography / methods
  • Humans
  • Inferior Wall Myocardial Infarction* / diagnosis
  • Inferior Wall Myocardial Infarction* / physiopathology
  • Inferior Wall Myocardial Infarction* / therapy
  • Male
  • Percutaneous Coronary Intervention / methods*
  • Purinergic P2Y Receptor Antagonists / administration & dosage
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • ST Elevation Myocardial Infarction* / diagnosis
  • ST Elevation Myocardial Infarction* / physiopathology
  • ST Elevation Myocardial Infarction* / therapy
  • Ticagrelor* / administration & dosage
  • Ticagrelor* / adverse effects
  • Treatment Outcome
  • Withholding Treatment

Substances

  • Purinergic P2Y Receptor Antagonists
  • Adenosine Monophosphate
  • cangrelor
  • Ticagrelor